Veracyte (VCYT) Stock Price, News & Analysis

Company Overview

Veracyte, Inc. (NASDAQ:VCYT) is a leading genomic diagnostics company that develops and commercializes tests designed to improve diagnostic accuracy and patient management in oncology and other critical disease areas. Founded in 2008 and headquartered in South San Francisco, California, Veracyte leverages next-generation sequencing and advanced bioinformatics to deliver minimally invasive tests that help clinicians make more informed decisions. The company operates CLIA-certified laboratories in the United States and Europe, serving a global network of physicians, pathologists and specialty clinics.

The company’s flagship Afirma test for thyroid nodules uses RNA expression analysis to distinguish benign from suspicious samples collected via fine-needle aspiration, reducing unnecessary surgeries. Its Percepta Bronchial Genomic Classifier analyzes airway epithelial cells obtained during bronchoscopy to assess lung cancer risk, while the Envisia Genomic Classifier aids in the diagnosis of idiopathic interstitial pneumonia. These tests address significant unmet needs by providing actionable insights, streamlining clinical pathways and potentially lowering overall healthcare costs.

Veracyte has also established strategic partnerships and licensing agreements to expand its portfolio, including rights to Prosigna, a breast cancer risk assessment assay, and collaborations with pharmaceutical companies to support drug development and companion diagnostic programs. The company’s tests are reimbursed by Medicare and a growing number of private insurers in the United States, with market access efforts underway in Europe and Asia to broaden patient reach.

Under the leadership of President and Chief Executive Officer Dr. Bonnie Anderson since 2015, Veracyte continues to invest in research and development to drive innovation across its diagnostic offerings. The executive team and board comprise seasoned experts in molecular diagnostics, life sciences and healthcare commercialization, all aligned with the company’s mission to transform patient care through precise, genomics-based solutions.

Key Stats

• Today's Range: $26.79 to $27.75
• 50-Day Range: $26.34 to $31.32
• 52-Week Range: $19.73 to $47.32
• Volume: 1.07 million shs
• Average Volume: 922,307 shs
• Market Capitalization: $2.12 billion
• P/E Ratio: 66.05
• Dividend Yield: N/A
• Price Target: $40.90
• Consensus Rating: Moderate Buy

Veracyte Stock Analysis - MarketRank™

Veracyte scored higher than 72% of companies evaluated by MarketBeat, and ranked 287th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Veracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 8 buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Veracyte has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: 5.88%

Earnings Growth

Earnings for Veracyte are expected to grow by 5.88% in the coming year, from $0.68 to $0.72 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Veracyte is 66.05, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.85.

Price to Earnings Ratio vs. Sector

The P/E ratio of Veracyte is 66.05, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.26.

Price to Book Value per Share Ratio

Veracyte has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.69% of the float of Veracyte has been sold short.

Short Interest Ratio / Days to Cover

Veracyte has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Veracyte has recently increased by 8.59%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Veracyte does not currently pay a dividend.

Dividend Growth

Veracyte does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.10

Percentage of Shares Shorted

7.69% of the float of Veracyte has been sold short.

Short Interest Ratio / Days to Cover

Veracyte has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Veracyte has recently increased by 8.59%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.93

News Sentiment

Veracyte has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Veracyte this week, compared to 7 articles on an average week.

Search Interest

7 people have searched for VCYT on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Veracyte to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Veracyte insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.40% of the stock of Veracyte is held by insiders.

VCYT Stock Analysis - Frequently Asked Questions

How have VCYT shares performed this year?

Veracyte's stock was trading at $39.60 at the start of the year. Since then, VCYT stock has decreased by 31.6% and is now trading at $27.08.

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) issued its quarterly earnings data on Monday, February, 24th. The biotechnology company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.29 by $0.07. The biotechnology company had revenue of $118.63 million for the quarter, compared to analyst estimates of $110.73 million. Veracyte had a trailing twelve-month return on equity of 6.14% and a net margin of 7.13%.
Read the conference call transcript.

Does Veracyte have any subsidiaries?

The following companies are subsidiaries of Veracyte: HalioDx Inc., Decipher Biosciences Inc., Allegro Diagnostics, Decipher Corp., Delight Merger Sub II LLC, Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.

Who are Veracyte's major shareholders?

Top institutional investors of Veracyte include Assenagon Asset Management S.A. (1.06%), Exchange Traded Concepts LLC (0.15%) and Wealth Enhancement Advisory Services LLC (0.02%). Insiders that own company stock include Rebecca Chambers, John Leite, Giulia C Kennedy, Bonnie H Anderson, Jonathan Wygant, Jonathan Wygant, Evan/ Fa Jones, John L Bishop, Jens Holstein, Muna Bhanji and Karin Eastham.
View institutional ownership trends.

How do I buy shares of Veracyte?

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Veracyte investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 2/24/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:VCYT
• CIK: 1384101
• Web: www.veracyte.com
• Phone: (650) 243-6300
• Fax: 650-243-6301
• Employees: 790
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Veracyte: $40.90
• High Price Target: $50.00
• Low Price Target: $28.00
• Potential Upside/Downside: +51.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.41
• Trailing P/E Ratio: 66.05
• Forward P/E Ratio: 39.82
• P/E Growth: N/A
• Net Income: $24.14 million
• Net Margins: 7.13%
• Pretax Margin: 7.57%
• Return on Equity: 6.14%
• Return on Assets: 5.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.10
• Quick Ratio: 4.78

Sales & Book Value

• Annual Sales: $463.39 million
• Price / Sales: 4.58
• Cash Flow: $1.04 per share
• Price / Cash Flow: 26.12
• Book Value: $15.17 per share
• Price / Book: 1.79

Miscellaneous

• Outstanding Shares: 78,315,000
• Free Float: 77,219,000
• Market Cap: $2.12 billion
• Optionable: Optionable
• Beta: 2.07